Total Funding
55
18
Total FundingSeed raised
Growth Score
-3 pts
Heat Score
0 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
190488
PolyProx Therapeutics is a developer of a novel class of drug intended to provide new therapies for cancer treatment.
- Andrew P Sandham: Executive ChairmanPast Role: Kymab, Chairman & CEO
- Laura S Itzhaki: Founder and Chief Scientific Officer
About the Company
PolyProx Therapeutics is developer of a novel class of drug intended to provide new therapies for cancer treatment. The company's drug will use novel engineered protein that is able to selectively target tumour cells and trigger natural degradation machinery within the cell, enabling cancer patients to benefit from the treatment that targets
and remove disease-causing proteins.
